Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

The global obesity epidemic is well established, with increases in obesity prevalence for
most countries since the 1980s. Obesity contributes directly to incident cardiovascular risk …

Despite decades of unequivocal evidence that waist circumference provides both
independent and additive information to BMI for predicting morbidity and risk of death, this …

Innovative non-pharmacological lifestyle strategies to treat non-alcoholic fatty liver disease
(NAFLD) are critically needed. This study compared the effects of alternate day fasting (ADF) …

Findings from epidemiological studies over the past 30 years have shown that visceral
adipose tissue, accurately measured by CT or MRI, is an independent risk marker of …

Abstract Background and Aims The effects of diet quality (DQ), physical activity (PA), and
socioeconomic status (SES) on the risk of NAFLD are unclear. We examined the association …

Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid
deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia …

Lifestyle intervention can be effective when treating non-alcoholic fatty liver diseases
(NAFLD) patients. Weight loss decreases cardiovascular and diabetes risk and can also …

The metabolic syndrome, by definition, is not a disease but is a clustering of individual
metabolic risk factors including abdominal obesity, hyperglycemia, hypertriglyceridemia …

NAFLD is closely linked with hepatic insulin resistance. Accumulation of hepatic
diacylglycerol activates PKC-ε, impairing insulin receptor activation and insulin-stimulated …